Observational studyFrontiers in endocrinology2026
Quality of life in refractory Graves' hyperthyroidism: a cross-sectional study comparing long-term ATDs therapy versus L-T4 replacement after iodine-131.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Evaluate and compare the patient-reported quality of life (QoL) outcomes in Graves' disease patients on long-term antithyroid drugs (ATDs) therapy and levothyroxine (L-T4) replacement after iodine-131, and explore factors influencing QoL. Methods: This single-center cross-sectional observational study included refractory Graves' hyperthyroidism patients who were followed in outpatient between January 2015 and July 2024. Patients were divided into two groups based on their current treatment: the ATDs group and the L-T4 group. We collected demographic and clinical characteristics and assessed cross-sectionally QoL using the thyroid-related patient-reported outcome-39 questionnaire (ThyPRO-39). We compared QoL scores between the two groups and examined factors associated with QoL using regression analyses. Results: A total of 499 patients were enrolled, of whom 300 completed the ThyPRO-39 (response rate 60.1%; 172 in the ATDs group and 128 in the L-T4 group). Compared with the ATDs group, patients in the L-T4 group had significantly higher scores across several subscales, including hyperthyroid symptoms, hypothyroid symptoms, eye symptoms, anxiety, emotional susceptibility, social life, daily life, appearance, overall QoL, and the composite scale (all P < 0.05), indicating lower QoL. In the multiple linear regression analysis, female was positively correlated with the scores of hypothyroidism symptoms, tiredness and depressivity (all P < 0.05). Male was negatively correlated with the score of the composite scale, while L-T4 group was positively correlated with the score of the composite scale (all P < 0.05). Conclusion: In patients with refractory Graves' hyperthyroidism, female patients and those undergoing long-term L-T4 replacement therapy after iodine-131 treatment were associated with lower QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.